Literature DB >> 18979512

Can NK cells be a therapeutic target in human cancer?

Christopher J Chan1, Daniel M Andrews, Mark J Smyth.   

Abstract

Our current knowledge of NK-cell recognition and effector function suggests that it will be possible to design various new NK-cell-based immunotherapies against human cancer. The application of NK cells is already showing promise using HLA-mismatched haematopoietic stem cell transplantation for treatment of haematological malignancies. A better understanding of NK-cell heterogeneity and function will only broaden the applications for human cancer. Here we review the key developments that will propel this field.

Entities:  

Mesh：

Year:  2008        PMID： 18979512     DOI： 10.1002/eji.200838764

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


  15 in total

1.  Transience in polarization of cytolytic effectors is required for efficient killing and controlled by Cdc42.

Authors:  Parisa Sinai; Chau Nguyen; John D Schatzle; Christoph Wülfing
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

2.  Tentative and transient natural killer cell polarization balances the requirements for discriminatory recognition and cytolytic efficacy.

Authors:  Parisa Sinai; Kole T Roybal; Christoph Wülfing
Journal:  Commun Integr Biol       Date:  2010-11-01

Review 3.  Mechanisms of NK cell activation: CD4(+) T cells enter the scene.

Authors:  Franck Bihl; Claire Germain; Carmelo Luci; Veronique M Braud
Journal:  Cell Mol Life Sci       Date:  2011-08-23       Impact factor: 9.261

4.  Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.

Authors:  Diego Sánchez-Martínez; Gemma Azaceta; Aura Muntasell; Nacho Aguiló; David Núñez; Eva M Gálvez; Javier Naval; Alberto Anel; Luis Palomera; Carlos Vilches; Isabel Marzo; Martín Villalba; Julián Pardo
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

5.  Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells.

Authors:  Daniel M Andrews; Lucy C Sullivan; Nikola Baschuk; Christopher J Chan; Richard Berry; Claire L Cotterell; Jie Lin; Heloise Halse; Sally V Watt; Jennifer Poursine-Laurent; Chyung-Ru Wang; Anthony A Scalzo; Wayne M Yokoyama; Jamie Rossjohn; Andrew G Brooks; Mark J Smyth
Journal:  Nat Immunol       Date:  2012-11-11       Impact factor: 25.606

Review 6.  Immunological effects and therapeutic role of C5a in cancer.

Authors:  Victoria R Darling; Ralph J Hauke; Stefano Tarantolo; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-12       Impact factor: 4.473

7.  Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.

Authors:  Lacey Gunn; Chuanlin Ding; Min Liu; Yunfeng Ma; Chunjian Qi; Yihua Cai; Xiaoling Hu; Deep Aggarwal; Huang-Ge Zhang; Jun Yan
Journal:  J Immunol       Date:  2012-08-22       Impact factor: 5.422

8.  Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis.

Authors:  Camille Guillerey; Melvyn T Chow; Kim Miles; Stuart Olver; Jaclyn Sceneay; Kazuyoshi Takeda; Andreas Möller; Mark J Smyth
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

9.  Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.

Authors:  Deepa Rajagopal; Carine Paturel; Yannis Morel; Satoshi Uematsu; Shizuo Akira; Sandra S Diebold
Journal:  Blood       Date:  2010-01-11       Impact factor: 22.113

10.  Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination.

Authors:  Daniel Scott-Algara; Maryline Mancini-Bourgine; Hélène Fontaine; Stanislas Pol; Marie-Louise Michel
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.